Jubilant Life Sciences receives ANDA approval for Quetiapine Fumarate Tablet

28 Nov 2013 Evaluate

Jubilant Life Sciences, an integrated Pharmaceuticals and Life Sciences Company has received Abbreviated New Drug Application (ANDA) approval from the US Food and Drug Administration (US FDA) for Quetiapine Fumarate Tablet, 25 mg (base), the generic version of AstraZeneca's Seroquel, which is an atypical antipsychotic medication indicated for the treatment of schizophrenia, and for the treatment of acute manic episodes associated with bipolar disorder. The current total market size for this product as per IMS is $59 million per annum.

Jubilant Life Sciences is a global Pharmaceutical and Life Sciences Company engaged in manufacture and supply of APIs, Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Life Science Ingredients. As on September 30, 2013, Jubilant Life Sciences had a total of 676 filings for formulations of which 218 have been approved in various regions of the world. This includes 58 ANDAs filed in the US and 48 Dossier filings in Europe.

Jubilant Pharmova Share Price

1067.50 4.45 (0.42%)
23-Dec-2024 12:05 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1824.55
Dr. Reddys Lab 1348.80
Cipla 1480.90
Lupin 2177.60
Zydus Lifesciences 979.30
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.